ARTH — Arch Therapeutics Share Price
0.000.00%
Last trade - 00:00- $4.98m
- $10.97m
- $0.08m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 0.06 | ||
| PEG Ratio (f) | 0 | ||
| EPS Growth (f) | 31.36% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 43.18 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -4563.79% | ||
Financial Summary
| Year End 30th Sep | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0.01 | 0.02 | 0.08 | 138 | 221.95 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | -58.05 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Arch Therapeutics, Inc. is a biotechnology company developing and marketing products based on its AC5 self-assembling technology platform. These products can be advances in the field of stasis and barrier applications. The Company’s flagship products and product candidates are derived from its AC5 self-assembling peptide (SAP) technology platform and referred to as AC5 or the AC5 Devices. These include AC5 Advanced Wound System and AC5 Topical Hemostat, which are intended for skin applications, such as management of complicated chronic wounds and acute surgical wounds. Other products are in development for use in minimally invasive or open surgical procedures and include AC5-GTM for gastrointestinal endoscopic procedures and AC5-V and AC5 Surgical Hemostat for hemostasis inside the body. It is developing BioSurgery products for internal use, including for hemostasis and sealant applications, and gastrointestinal endoscopic surgical procedures.
Directors
- Terrence Norchi CHM (49)
- Richard Davis CFO (55)
- Guy Fish DRC (62)
- Laurence Hicks DRC (55)
- Punit Dhillon IND (40)
- Last Annual
- September 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 16th, 2009
- Public Since
- June 27th, 2012
- No. of Shareholders
- 130
- No. of Employees
- 8
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 4,742,364
- Address
- 235 Walnut Street, Suite 6, FRAMINGHAM, 01702
- Web
- https://www.archtherapeutics.com/
- Phone
- +1 6174312313
- Auditors
- BAKER TILLY US LLP
Upcoming Events for ARTH
Q3 2024 Arch Therapeutics Inc Earnings Release
Similar to ARTH
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
Aksys
Pink Sheets on Nasdaq
FAQ
What is the Arch Therapeutics share price?
As of Today at 19:02 UTC, shares in Arch Therapeutics are trading at $1.05. This share price information is delayed by 15 minutes.
How has the Arch Therapeutics share price performed this year?
Shares in Arch Therapeutics last closed at $1.05 and the price had moved by -70% over the past 365 days. In terms of relative price strength the Arch Therapeutics share price has underperformed the S&P500 Index by -73.53% over the past year.
What are the analyst and broker recommendations for Arch Therapeutics?
The overall consensus recommendation for Arch Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Arch Therapeutics dividend yield?
Arch Therapeutics does not currently pay a dividend.
Does Arch Therapeutics pay a dividend?
Arch Therapeutics does not currently pay a dividend.
When does Arch Therapeutics next pay dividends?
Arch Therapeutics does not currently pay a dividend.
How do I buy Arch Therapeutics shares?
To buy shares in Arch Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Arch Therapeutics?
As of the previous close price of $1.05, shares in Arch Therapeutics had a market capitalisation of $4.98m.
Where are Arch Therapeutics shares listed?
Here are the trading details for Arch Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ARTH
What kind of share is Arch Therapeutics?
Based on an overall assessment of its quality, value and momentum Arch Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Arch Therapeutics share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Arch Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arch Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +50.86%.
As of the last closing price of $1.05, shares in Arch Therapeutics were trading -63.79% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Arch Therapeutics PE Ratio?
The Arch Therapeutics PE ratio based on its reported earnings over the past 12 months is 0.06. The shares last closed at $1.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Arch Therapeutics?
Arch Therapeutics' management team is headed by:
- Terrence Norchi - CHM
- Richard Davis - CFO
- Guy Fish - DRC
- Laurence Hicks - DRC
- Punit Dhillon - IND